Roe-Pharma, a Canadian Drug Company, Obtained a Licence from Mega-Mega-Pharma

Roe-Pharma, a Canadian drug company, obtained a licence from Mega-mega-Pharma, a Swiss drug company, to sell Heptamyoextropalol in Canada. Reo-Pharma sells this patented medicine for $15 per pill. Generic Drugs Inc., another Canadian company, says that it can sell this drug for $2.50 per pill. Which of the following is true?

A) GDI can apply for a compulsory licence but it will not be granted because Reo-Pharma is using the patent.
B) GDI cannot apply for a compulsory licence pursuant to the Patent Law Amendment Act, 1992.
C) GDI will likely be granted a compulsory licence under the Patent Act because the price at which this drug is currently being sold is so high.
D) The Patented Medicine Price Review Board may reduce the price of Heptamyoextropalol if it feels it is excessive.
E) Both B and D